Advancing Precision Medicine Through Comprehensive Genomic Profiling (CGP)

Health care professionals in oncology comment on the evolving concept of precision medicine in cancer care and the role of comprehensive genomic profiling.

Payer perspective regarding updates to coverage for comprehensive genomic profiling, becoming more widely used in oncology practice.

Information that can be extracted from results of comprehensive genomic profiling assays and used to guide treatment decisions in oncology.

Considerations regarding coverage decisions to support the large amount of information provided by molecular testing assays and the validity of results in terms of clinical decision-making.

How the identification of certain driver mutations analyzed by genomic assays can be applied into oncology treatment.

Oncologists who manage patients with solid tumors compare and contrast current comprehensive molecular assays being used in clinical practice and discuss reimbursement criteria with payer, Eugean Jiwanmall, MPH, MBA.

The rationale for migrating away from single, spot testing to comprehensive genomic profiling assays in oncology.

How to determine what information from comprehensive genomic profiling assays is relevant vs extraneous when making treatment decisions for patients with solid tumor cancers.

Oncologists describe how they use molecular profiling in their practices to assess patients with solid tumor cancers.

Payer response to supporting decisions for coverage of comprehensive genomic profiling in oncology.

Criteria used by payers to determine how to code and support the use of various genomic profiling assays used in oncology.

Oncologists explain scenarios for which they may retest patients previously assessed via genomic profiling.

Variables that impact decisions to initiate therapy for solid tumor cancers versus wait for results of genomic profiling assays.

Payer perspective regarding decisions for covering the costs of molecular assays in oncology and reimbursing oncologists for treatments provided to patients while navigating long turnaround times associated with reflex testing.

Expectations regarding the future utilization of comprehensive genomic profiling in clinical practice to assess patients with solid tumor cancers.

How payers will support the use of comprehensive genomic profiling in oncology moving forward.

Recommendations to address limitations in more widespread use of reflex testing in community oncology.